Long- and Short-Term Cost-Effectiveness of Once-Weekly Semaglutide versus Dulaglutide for the Treatment of Type 2 Diabetes in China: A Hypothetical Modeling Exercise

被引：0
|
作者：
Ying Hu [1 ]
Huimin Zou [2 ]
Yang Shen [3 ]
Qi Ni [4 ]
Yijun Li [1 ]
Hao Zhang [1 ]
Xianwen Chen [5 ]
Carolina Oi Lam Ung [2 ]
Hao Hu [2 ]
Yiming Mu [6 ]
机构：
[1] PLA General Hospital,Department of Endocrinology, First Medical Center of Chinese
[2] University of Macau,State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences
[3] Peking University,School of Public Health
[4] Peking University,China Center for Health Development Studies
[5] Novo Nordisk (China) Pharmaceuticals Co.,Centre for Pharmaceutical Regulatory Sciences
[6] Ltd.,Department of Public Health and Medicinal Administration, Faculty of Health Sciences
[7] University of Macau,undefined
[8] University of Macau,undefined
来源：
Diabetes Therapy | 2025年 / 16卷 / 5期
关键词：
Type 2 diabetes; Semaglutide; Dulaglutide; Cost-effectiveness analysis; China;
D O I：
10.1007/s13300-025-01716-9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：915 / 929
页数：14
相关论文
共 50 条
  • [1] The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
    Vidal, Josep
    Malkin, Samuel J. P.
    Hunt, Barnaby
    Martin, Virginia
    Hallen, Nino
    Javier Ortega, Francisco
    DIABETES THERAPY, 2020, 11 (02) : 509 - 521
  • [2] The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
    Josep Vidal
    Samuel J. P. Malkin
    Barnaby Hunt
    Virginia Martín
    Nino Hallén
    Francisco Javier Ortega
    Diabetes Therapy, 2020, 11 : 509 - 521
  • [3] The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
    Shuyan Gu
    Jinghong Gu
    Xiaoyong Wang
    Xiaoling Wang
    Lu Li
    Hai Gu
    Biao Xu
    Health Economics Review, 14
  • [4] The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
    Gu, Shuyan
    Gu, Jinghong
    Wang, Xiaoyong
    Wang, Xiaoling
    Li, Lu
    Gu, Hai
    Xu, Biao
    HEALTH ECONOMICS REVIEW, 2024, 14 (01)
  • [5] Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China
    Ruan, Zhen
    Ung, Carolina Oi Lam
    Shen, Yang
    Zhang, Yawen
    Wang, Weihao
    Luo, Jingyi
    Zou, Huimin
    Xue, Yan
    Wang, Yao
    Hu, Hao
    Guo, Lixin
    DIABETES THERAPY, 2022, 13 (10) : 1737 - 1753
  • [6] Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China
    Zhen Ruan
    Carolina Oi Lam Ung
    Yang Shen
    Yawen Zhang
    Weihao Wang
    Jingyi Luo
    Huimin Zou
    Yan Xue
    Yao Wang
    Hao Hu
    Lixin Guo
    Diabetes Therapy, 2022, 13 : 1737 - 1753
  • [7] The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia
    Malkin, Samuel J. P.
    Russel-Szymczyk, Monika
    Psota, Marek
    Hlavinkova, Lucia
    Hunt, Barnaby
    ADVANCES IN THERAPY, 2019, 36 (08) : 2034 - 2051
  • [8] The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia
    Samuel J. P. Malkin
    Monika Russel-Szymczyk
    Marek Psota
    Lucia Hlavinkova
    Barnaby Hunt
    Advances in Therapy, 2019, 36 : 2034 - 2051
  • [9] Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
    Ataru Igarashi
    Barnaby Hunt
    Lars Wilkinson
    Jakob Langer
    Richard F. Pollock
    Advances in Therapy, 2020, 37 : 4446 - 4457
  • [10] Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
    Igarashi, Ataru
    Hunt, Barnaby
    Wilkinson, Lars
    Langer, Jakob
    Pollock, Richard F.
    ADVANCES IN THERAPY, 2020, 37 (10) : 4446 - 4457
12345